BioCentury | Oct 10, 2016
Clinical News

Cebranopadol: Phase III data

...with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol...
...non-inferiority margin was 8 mg. Cebranopadol was also superior to morphine on the endpoint (p=0.0016). Cebranopadol...
...the knee. Depomed Inc. (NASDAQ:DEPO), Newark, Calif. Gruenenthal Group , Aachen, Germany Product: Cebranopadol ( GRT6005...
BioCentury | Sep 30, 2016
Clinical News

Gruenenthal's cebranopadol meets Phase III pain endpoint

...Gruenenthal Group (Aachen, Germany) said once-daily cebranopadol ( GRT6005 ) met the primary endpoint of a...
...the primary endpoint of a Phase III study to treat cancer-related pain. The company said cebranopadol...
...medication over the last two weeks of the trial's maintenance phase (p<0.05). The company said cebranopadol...
BioCentury | Dec 14, 2015
Company News

Gruenenthal, Depomed deal

...Gruenenthal will grant Depomed exclusive rights to develop and commercialize cebranopadol in the U.S. and Canada...
BioCentury | Dec 15, 2014
Company News

Gruenenthal, Forest Laboratories deal

...2010 deal granting Actavis’ subsidiary, Forest Laboratories, exclusive rights to co-develop and commercialize cebranopadol ( GRT6005...
BioCentury | Jan 24, 2011
Finance

Less VC, more SBIR

...with Gruenenthal Group granting Forest U.S. and Canadian rights to co-develop and commercialize pain candidates GRT6005...
BioCentury | Dec 13, 2010
Finance

Regulatory Milestones

...the U.S. and Canada to co-develop and commercialize GRT6005 and follow-on compound GRT6006 for pain. GRT6005...
BioCentury | Dec 13, 2010
Company News

Forest Laboratories, Gruenenthal deal

Gruenenthal granted Forest exclusive rights in the U.S. and Canada to co-develop and commercialize two candidates for pain. GRT 6005 and follow-on compound GRT 6006 are agonists of opioid receptor (OPR) and mu opioid receptor...
BioCentury | Dec 7, 2010
Company News

Forest, Gruenenthal unveil pain deal

...exclusive rights in the U.S. and Canada to co-develop and commercialize two candidates for pain. GRT6005...
...GRT6006 are agonists of opioid receptor (OPR) and mu opioid receptor ( OPRM1 ; MOR). GRT6005...
Items per page:
1 - 8 of 8